Blog
RSS FeedPosted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 12 Oct 2022
SQ HDM SLIT for the treatment of patients with allergic rhinitis and allergic asthma caused by house dust mites
12 October 2022 - NICE is unable to make a recommendation on the use of SQ HDM SLIT (Acarizax) for the ...
Posted by Michael Wonder on 05 Oct 2022
Ozanimod hydrochloride for treating moderate to severe active ulcerative colitis
5 October 2022 - NICE has published evidence based recommendations on the use of ozanimod hydrochloride for the treatment of ...
Posted by Michael Wonder on 05 Oct 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
5 October 2022 - NICE has published evidence based recommendations on the use of azacitidine for the maintenance treatment of ...
Posted by Michael Wonder on 30 Sep 2022
NICE review does not recommend routine funding for Duchenne muscular dystrophy gene therapy ataluren in draft guidance
30 September 2022 - NICE has today published draft guidance for public consultation which does not recommend ataluren (Translarna, PTC Therapeutics) ...
Posted by Michael Wonder on 28 Sep 2022
News “hyperbole” in Government media releases on new drugs can undermine confidence in NHS, says editor
28 September 2022 - Phrases such as “cutting edge,” “game changing,” and “ground breaking” have no place in the description ...
Posted by Michael Wonder on 28 Sep 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with ...
Posted by Michael Wonder on 23 Sep 2022
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning and spreading
23 September 2022 - Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also ...
Posted by Michael Wonder on 23 Sep 2022
NICE approves routine use of drug combination for advanced breast cancer
23 September 2022 - Another life-extending drug combination for some people with advanced breast cancer will now be available for routine ...
Posted by Michael Wonder on 23 Sep 2022
Vedolizumab for the treatment of patients with chronic refractory pouchitis
21 September 2022 - NICE is unable to make a recommendation about the use in the NHS of vedolizumab for the ...
Posted by Michael Wonder on 14 Sep 2022
Dexamethasone intravitreal implant for treating diabetic macular oedema
14 September 2022 - NICE has published evidence-based recommendations on the use of dexamethasone intravitreal implant for the treatment of ...
Posted by Michael Wonder on 14 Sep 2022
NICE inks another early full stop on the appraisal of a cancer medicine
14 September 2022 - Once again, the sponsor decided not to provide an evidence submission. ...
Posted by Michael Wonder on 31 Aug 2022
Brolucizumab for treating diabetic macular oedema
31 August 2022 - NICE has published evidence-based recommendations on the use of brolucizumab (Beovu) for the treatment of adults ...
Posted by Michael Wonder on 24 Aug 2022
Avalglucosidase alfa for treating Pompe disease
24 August 2022 - NICE has published evidence-based recommendations on the use of avalglucosidase alfa for the treatment of patients ...
Posted by Michael Wonder on 18 Aug 2022
CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos
18 August 2022 - UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently approved therapy for two ...